epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Qulipta

atogepant

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  TAB: 10 mg, 30 mg, 60 mg

migraine prophylaxis, episodic

[10-60 mg PO qd]

migraine prophylaxis, chronic

[60 mg PO qd]

renal dosing

[migraine prophylaxis, episodic]
CrCl <30: 10 mg qd
HD: 10 mg qd, on dialysis days administer after dialysis; no supplement; PD: not defined
[migraine prophylaxis, chronic]
CrCl <30: not defined, caution advised
HD/PD: not defined

hepatic dosing

[see below]
Child-Pugh Class C: avoid use

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@33ed8feb
  • hypersensitivity to drug or ingredient
  • hepatic impairment, Child-Pugh Class C
  • caution: CrCl <30
  • caution: HTN
  • caution: Raynaud phenomenon

Drug Interactions .

Overview

atogepant

CGRP antagonist

Interaction Characteristics:
  • CYP3A4 substrate
  • OATP1B1 substrate
  • OATP1B3 substrate
  • hypertensive effects

Avoid/Use Alternative

  • apalutamide
  • Qulipta (atogepant)
    +
    apalutamide
    1 interaction

    Avoid/Use Alternative

    atogepant + apalutamide

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • atogepant
  • Qulipta (atogepant)
    +
    atogepant
    1 interaction

    Avoid/Use Alternative

    atogepant + atogepant

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • bosentan
  • Qulipta (atogepant)
    +
    bosentan
    1 interaction

    Avoid/Use Alternative

    atogepant + bosentan

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • butalbital
  • Qulipta (atogepant)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    atogepant + butalbital

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • carbamazepine
  • Qulipta (atogepant)
    +
    carbamazepine
    1 interaction

    Avoid/Use Alternative

    atogepant + carbamazepine

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • cenobamate
  • Qulipta (atogepant)
    +
    cenobamate
    1 interaction

    Avoid/Use Alternative

    atogepant + cenobamate

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • dabrafenib
  • Qulipta (atogepant)
    +
    dabrafenib
    1 interaction

    Avoid/Use Alternative

    atogepant + dabrafenib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • efavirenz
  • Qulipta (atogepant)
    +
    efavirenz
    1 interaction

    Avoid/Use Alternative

    atogepant + efavirenz

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • encorafenib
  • Qulipta (atogepant)
    +
    encorafenib
    1 interaction

    Avoid/Use Alternative

    atogepant + encorafenib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: consider atogepant dose adjustment: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

  • enzalutamide
  • Qulipta (atogepant)
    +
    enzalutamide
    1 interaction

    Avoid/Use Alternative

    atogepant + enzalutamide

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • epinephrine inhaled
  • Qulipta (atogepant)
    +
    epinephrine inhaled
    1 interaction

    Avoid/Use Alternative

    atogepant + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • eptinezumab
  • Qulipta (atogepant)
    +
    eptinezumab
    1 interaction

    Avoid/Use Alternative

    atogepant + eptinezumab

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • erenumab
  • Qulipta (atogepant)
    +
    erenumab
    1 interaction

    Avoid/Use Alternative

    atogepant + erenumab

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • etravirine
  • Qulipta (atogepant)
    +
    etravirine
    1 interaction

    Avoid/Use Alternative

    atogepant + etravirine

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • fexinidazole
  • Qulipta (atogepant)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    atogepant + fexinidazole

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • fosphenytoin
  • Qulipta (atogepant)
    +
    fosphenytoin
    1 interaction

    Avoid/Use Alternative

    atogepant + fosphenytoin

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • fremanezumab
  • Qulipta (atogepant)
    +
    fremanezumab
    1 interaction

    Avoid/Use Alternative

    atogepant + fremanezumab

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • furosemide
  • Qulipta (atogepant)
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    atogepant + furosemide

    use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • galcanezumab
  • Qulipta (atogepant)
    +
    galcanezumab
    1 interaction

    Avoid/Use Alternative

    atogepant + galcanezumab

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • ivosidenib
  • Qulipta (atogepant)
    +
    ivosidenib
    1 interaction

    Avoid/Use Alternative

    atogepant + ivosidenib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • lopinavir/ritonavir
  • Qulipta (atogepant)
    +
    lopinavir/ ritonavir
    1 interaction

    Avoid/Use Alternative

    atogepant + lopinavir/ ritonavir

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: consider atogepant dose adjustment: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered, hepatic transport inhibited)

  • lorlatinib
  • Qulipta (atogepant)
    +
    lorlatinib
    1 interaction

    Avoid/Use Alternative

    atogepant + lorlatinib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: monitor BP; incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • lumacaftor/ivacaftor
  • Qulipta (atogepant)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Avoid/Use Alternative

    atogepant + lumacaftor/ ivacaftor

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: monitor BP; incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • mavacamten
  • Qulipta (atogepant)
    +
    mavacamten
    1 interaction

    Avoid/Use Alternative

    atogepant + mavacamten

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • midodrine
  • Qulipta (atogepant)
    +
    midodrine
    1 interaction

    Avoid/Use Alternative

    atogepant + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

  • mitapivat
  • Qulipta (atogepant)
    +
    mitapivat
    1 interaction

    Avoid/Use Alternative

    atogepant + mitapivat

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • mitotane
  • Qulipta (atogepant)
    +
    mitotane
    1 interaction

    Avoid/Use Alternative

    atogepant + mitotane

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • modafinil
  • Qulipta (atogepant)
    +
    modafinil
    1 interaction

    Avoid/Use Alternative

    atogepant + modafinil

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: monitor BP; incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • nafcillin
  • Qulipta (atogepant)
    +
    nafcillin
    1 interaction

    Avoid/Use Alternative

    atogepant + nafcillin

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • pacritinib
  • Qulipta (atogepant)
    +
    pacritinib
    1 interaction

    Avoid/Use Alternative

    atogepant + pacritinib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • pentobarbital
  • Qulipta (atogepant)
    +
    pentobarbital
    1 interaction

    Avoid/Use Alternative

    atogepant + pentobarbital

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • pexidartinib
  • Qulipta (atogepant)
    +
    pexidartinib
    1 interaction

    Avoid/Use Alternative

    atogepant + pexidartinib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: monitor BP; incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • phenobarbital
  • Qulipta (atogepant)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    atogepant + phenobarbital

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • phenytoin
  • Qulipta (atogepant)
    +
    phenytoin
    1 interaction

    Avoid/Use Alternative

    atogepant + phenytoin

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • primidone
  • Qulipta (atogepant)
    +
    primidone
    1 interaction

    Avoid/Use Alternative

    atogepant + primidone

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • repotrectinib
  • Qulipta (atogepant)
    +
    repotrectinib
    1 interaction

    Avoid/Use Alternative

    atogepant + repotrectinib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • rifabutin
  • Qulipta (atogepant)
    +
    rifabutin
    1 interaction

    Avoid/Use Alternative

    atogepant + rifabutin

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • rifampin
  • Qulipta (atogepant)
    +
    rifampin
    1 interaction

    Avoid/Use Alternative

    atogepant + rifampin

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: consider atogepant dose adjustment: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

  • rifapentine
  • Qulipta (atogepant)
    +
    rifapentine
    1 interaction

    Avoid/Use Alternative

    atogepant + rifapentine

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • rimegepant
  • Qulipta (atogepant)
    +
    rimegepant
    1 interaction

    Avoid/Use Alternative

    atogepant + rimegepant

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • sotorasib
  • Qulipta (atogepant)
    +
    sotorasib
    1 interaction

    Avoid/Use Alternative

    atogepant + sotorasib

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • St. John's wort
  • Qulipta (atogepant)
    +
    St. John's wort
    1 interaction

    Avoid/Use Alternative

    atogepant + St. John's wort

    CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • ubrogepant
  • Qulipta (atogepant)
    +
    ubrogepant
    1 interaction

    Avoid/Use Alternative

    atogepant + ubrogepant

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

  • zavegepant
  • Qulipta (atogepant)
    +
    zavegepant
    1 interaction

    Avoid/Use Alternative

    atogepant + zavegepant

    avoid combo: combo may incr. risk of HTN, other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

  • abiraterone acetate
  • Qulipta (atogepant)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    atogepant + abiraterone acetate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • acebutolol
  • Qulipta (atogepant)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    atogepant + acebutolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • adagrasib
  • Qulipta (atogepant)
    +
    adagrasib
    1 interaction

    Monitor/Modify Tx

    atogepant + adagrasib

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • albuterol
  • Qulipta (atogepant)
    +
    albuterol
    1 interaction

    Monitor/Modify Tx

    atogepant + albuterol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • albuterol inhaled
  • Qulipta (atogepant)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + albuterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aliskiren
  • Qulipta (atogepant)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    atogepant + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • almotriptan
  • Qulipta (atogepant)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • amiloride
  • Qulipta (atogepant)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    atogepant + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amlodipine
  • Qulipta (atogepant)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    atogepant + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amphetamine
  • Qulipta (atogepant)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    atogepant + amphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • angiotensin II
  • Qulipta (atogepant)
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    atogepant + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aprocitentan
  • Qulipta (atogepant)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    atogepant + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • arformoterol inhaled
  • Qulipta (atogepant)
    +
    arformoterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + arformoterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • armodafinil
  • Qulipta (atogepant)
    +
    armodafinil
    1 interaction

    Monitor/Modify Tx

    atogepant + armodafinil

    monitor BP; CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • artemether/lumefantrine
  • Qulipta (atogepant)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    atogepant + artemether/ lumefantrine

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • asciminib
  • Qulipta (atogepant)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    atogepant + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atazanavir
  • Qulipta (atogepant)
    +
    atazanavir
    1 interaction

    Monitor/Modify Tx

    atogepant + atazanavir

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • atenolol
  • Qulipta (atogepant)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    atogepant + atenolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • atomoxetine
  • Qulipta (atogepant)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    atogepant + atomoxetine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atropine ophthalmic
  • Qulipta (atogepant)
    +
    atropine ophthalmic
    1 interaction

    Monitor/Modify Tx

    atogepant + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • axitinib
  • Qulipta (atogepant)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    atogepant + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • azilsartan medoxomil
  • Qulipta (atogepant)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    atogepant + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • belumosudil
  • Qulipta (atogepant)
    +
    belumosudil
    1 interaction

    Monitor/Modify Tx

    atogepant + belumosudil

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • belzutifan
  • Qulipta (atogepant)
    +
    belzutifan
    1 interaction

    Monitor/Modify Tx

    atogepant + belzutifan

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • bempedoic acid
  • Qulipta (atogepant)
    +
    bempedoic acid
    1 interaction

    Monitor/Modify Tx

    atogepant + bempedoic acid

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • benazepril
  • Qulipta (atogepant)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    atogepant + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benzphetamine
  • Qulipta (atogepant)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    atogepant + benzphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • betamethasone
  • Qulipta (atogepant)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    atogepant + betamethasone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • betaxolol
  • Qulipta (atogepant)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    atogepant + betaxolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bevacizumab
  • Qulipta (atogepant)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    atogepant + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bexarotene
  • Qulipta (atogepant)
    +
    bexarotene
    1 interaction

    Monitor/Modify Tx

    atogepant + bexarotene

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • bismuth subsalicylate
  • Qulipta (atogepant)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    atogepant + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • bisoprolol
  • Qulipta (atogepant)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    atogepant + bisoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • brigatinib
  • Qulipta (atogepant)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    atogepant + brigatinib

    monitor BP; CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • budesonide
  • Qulipta (atogepant)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    atogepant + budesonide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bumetanide
  • Qulipta (atogepant)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    atogepant + bumetanide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bupropion
  • Qulipta (atogepant)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    atogepant + bupropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cabozantinib
  • Qulipta (atogepant)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    atogepant + cabozantinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • caffeine
  • Qulipta (atogepant)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    atogepant + caffeine

    monitor BP; avoid excessive caffeine intake: combo may incr. risk of HTN (additive effects)

  • caffeine citrate
  • Qulipta (atogepant)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    atogepant + caffeine citrate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • candesartan cilexetil
  • Qulipta (atogepant)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    atogepant + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cannabis
  • Qulipta (atogepant)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    atogepant + cannabis

    monitor BP: combo may incr. risk of HTN (additive effects)

  • captopril
  • Qulipta (atogepant)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    atogepant + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carfilzomib
  • Qulipta (atogepant)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    atogepant + carfilzomib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • carvedilol
  • Qulipta (atogepant)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    atogepant + carvedilol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ceftobiprole
  • Qulipta (atogepant)
    +
    ceftobiprole
    1 interaction

    Monitor/Modify Tx

    atogepant + ceftobiprole

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport possibly inhibited)

  • celecoxib
  • Qulipta (atogepant)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    atogepant + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ceritinib
  • Qulipta (atogepant)
    +
    ceritinib
    1 interaction

    Monitor/Modify Tx

    atogepant + ceritinib

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • chloramphenicol
  • Qulipta (atogepant)
    +
    chloramphenicol
    1 interaction

    Monitor/Modify Tx

    atogepant + chloramphenicol

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • chlorothiazide
  • Qulipta (atogepant)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    atogepant + chlorothiazide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • chlorthalidone
  • Qulipta (atogepant)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    atogepant + chlorthalidone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clarithromycin
  • Qulipta (atogepant)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    atogepant + clarithromycin

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • clevidipine
  • Qulipta (atogepant)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    atogepant + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clobazam
  • Qulipta (atogepant)
    +
    clobazam
    1 interaction

    Monitor/Modify Tx

    atogepant + clobazam

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • clonidine
  • Qulipta (atogepant)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    atogepant + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clopidogrel
  • Qulipta (atogepant)
    +
    clopidogrel
    1 interaction

    Monitor/Modify Tx

    atogepant + clopidogrel

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • cobicistat
  • Qulipta (atogepant)
    +
    cobicistat
    1 interaction

    Monitor/Modify Tx

    atogepant + cobicistat

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • cocaine
  • Qulipta (atogepant)
    +
    cocaine
    1 interaction

    Monitor/Modify Tx

    atogepant + cocaine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • copanlisib
  • Qulipta (atogepant)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    atogepant + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

  • corticotropin
  • Qulipta (atogepant)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    atogepant + corticotropin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cortisone
  • Qulipta (atogepant)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    atogepant + cortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cyclosporine
  • Qulipta (atogepant)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    atogepant + cyclosporine

    monitor BP; CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of HTN, other adverse effects (hepatic transport inhibited, additive effects)

  • danazol
  • Qulipta (atogepant)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    atogepant + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • danshen
  • Qulipta (atogepant)
    +
    danshen
    1 interaction

    Monitor/Modify Tx

    atogepant + danshen

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • darbepoetin alfa
  • Qulipta (atogepant)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    atogepant + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • darolutamide
  • Qulipta (atogepant)
    +
    darolutamide
    1 interaction

    Monitor/Modify Tx

    atogepant + darolutamide

    consider atogepant dose adjustment: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

  • darunavir
  • Qulipta (atogepant)
    +
    darunavir
    1 interaction

    Monitor/Modify Tx

    atogepant + darunavir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • deflazacort
  • Qulipta (atogepant)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    atogepant + deflazacort

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desmopressin
  • Qulipta (atogepant)
    +
    desmopressin
    1 interaction

    Monitor/Modify Tx

    atogepant + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desvenlafaxine
  • Qulipta (atogepant)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    atogepant + desvenlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dexamethasone
  • Qulipta (atogepant)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    atogepant + dexamethasone

    monitor BP; CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • dexmethylphenidate
  • Qulipta (atogepant)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    atogepant + dexmethylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dextroamphetamine
  • Qulipta (atogepant)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    atogepant + dextroamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac
  • Qulipta (atogepant)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    atogepant + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac topical
  • Qulipta (atogepant)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    atogepant + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dicloxacillin
  • Qulipta (atogepant)
    +
    dicloxacillin
    1 interaction

    Monitor/Modify Tx

    atogepant + dicloxacillin

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • diethylpropion
  • Qulipta (atogepant)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    atogepant + diethylpropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diflunisal
  • Qulipta (atogepant)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    atogepant + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dihydroergotamine
  • Qulipta (atogepant)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    atogepant + dihydroergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • diltiazem
  • Qulipta (atogepant)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    atogepant + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dobutamine
  • Qulipta (atogepant)
    +
    dobutamine
    1 interaction

    Monitor/Modify Tx

    atogepant + dobutamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dopamine
  • Qulipta (atogepant)
    +
    dopamine
    1 interaction

    Monitor/Modify Tx

    atogepant + dopamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxapram
  • Qulipta (atogepant)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    atogepant + doxapram

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxazosin
  • Qulipta (atogepant)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    atogepant + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dronabinol
  • Qulipta (atogepant)
    +
    dronabinol
    1 interaction

    Monitor/Modify Tx

    atogepant + dronabinol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • droxidopa
  • Qulipta (atogepant)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    atogepant + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

  • echinacea
  • Qulipta (atogepant)
    +
    echinacea
    1 interaction

    Monitor/Modify Tx

    atogepant + echinacea

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • elafibranor
  • Qulipta (atogepant)
    +
    elafibranor
    1 interaction

    Monitor/Modify Tx

    atogepant + elafibranor

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • elagolix
  • Qulipta (atogepant)
    +
    elagolix
    1 interaction

    Monitor/Modify Tx

    atogepant + elagolix

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • eletriptan
  • Qulipta (atogepant)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eltrombopag
  • Qulipta (atogepant)
    +
    eltrombopag
    1 interaction

    Monitor/Modify Tx

    atogepant + eltrombopag

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • eluxadoline
  • Qulipta (atogepant)
    +
    eluxadoline
    1 interaction

    Monitor/Modify Tx

    atogepant + eluxadoline

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • enalapril
  • Qulipta (atogepant)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    atogepant + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Qulipta (atogepant)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    atogepant + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enasidenib
  • Qulipta (atogepant)
    +
    enasidenib
    1 interaction

    Monitor/Modify Tx

    atogepant + enasidenib

    consider atogepant dose adjustment: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

  • ephedra
  • Qulipta (atogepant)
    +
    ephedra
    1 interaction

    Monitor/Modify Tx

    atogepant + ephedra

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine injection
  • Qulipta (atogepant)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    atogepant + ephedrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine oral
  • Qulipta (atogepant)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    atogepant + ephedrine oral

    monitor BP: combo may incr. risk of HTN (additive effects)

  • epinephrine
  • Qulipta (atogepant)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    atogepant + epinephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eplerenone
  • Qulipta (atogepant)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    atogepant + eplerenone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epoetin alfa
  • Qulipta (atogepant)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    atogepant + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ergotamine
  • Qulipta (atogepant)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    atogepant + ergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • erythromycin
  • Qulipta (atogepant)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    atogepant + erythromycin

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • esketamine
  • Qulipta (atogepant)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    atogepant + esketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eslicarbazepine acetate
  • Qulipta (atogepant)
    +
    eslicarbazepine acetate
    1 interaction

    Monitor/Modify Tx

    atogepant + eslicarbazepine acetate

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • esmolol
  • Qulipta (atogepant)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    atogepant + esmolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • estetrol (contraceptive)
  • Qulipta (atogepant)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    atogepant + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • estradiol (contraceptive)
  • Qulipta (atogepant)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    atogepant + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ethacrynic acid
  • Qulipta (atogepant)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    atogepant + ethacrynic acid

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ethanol (alcoholic beverage)
  • Qulipta (atogepant)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    atogepant + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • ethinyl estradiol (contraceptive)
  • Qulipta (atogepant)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    atogepant + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etodolac
  • Qulipta (atogepant)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    atogepant + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etrasimod
  • Qulipta (atogepant)
    +
    etrasimod
    1 interaction

    Monitor/Modify Tx

    atogepant + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • felbamate
  • Qulipta (atogepant)
    +
    felbamate
    1 interaction

    Monitor/Modify Tx

    atogepant + felbamate

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • felodipine
  • Qulipta (atogepant)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    atogepant + felodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenfluramine
  • Qulipta (atogepant)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    atogepant + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenoldopam
  • Qulipta (atogepant)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    atogepant + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Qulipta (atogepant)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    atogepant + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fingolimod
  • Qulipta (atogepant)
    +
    fingolimod
    1 interaction

    Monitor/Modify Tx

    atogepant + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fludrocortisone
  • Qulipta (atogepant)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    atogepant + fludrocortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • flurbiprofen
  • Qulipta (atogepant)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    atogepant + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • formoterol inhaled
  • Qulipta (atogepant)
    +
    formoterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + formoterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fosamprenavir
  • Qulipta (atogepant)
    +
    fosamprenavir
    1 interaction

    Monitor/Modify Tx

    atogepant + fosamprenavir

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • fosinopril
  • Qulipta (atogepant)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    atogepant + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fostamatinib
  • Qulipta (atogepant)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    atogepant + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fostemsavir
  • Qulipta (atogepant)
    +
    fostemsavir
    1 interaction

    Monitor/Modify Tx

    atogepant + fostemsavir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • frovatriptan
  • Qulipta (atogepant)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Qulipta (atogepant)
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    atogepant + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • garlic
  • Qulipta (atogepant)
    +
    garlic
    1 interaction

    Monitor/Modify Tx

    atogepant + garlic

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy with supplemental garlic; dietary intake OK (hepatic metabolism induced)

  • gemfibrozil
  • Qulipta (atogepant)
    +
    gemfibrozil
    1 interaction

    Monitor/Modify Tx

    atogepant + gemfibrozil

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • ginkgo
  • Qulipta (atogepant)
    +
    ginkgo
    1 interaction

    Monitor/Modify Tx

    atogepant + ginkgo

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • ginseng, Asian
  • Qulipta (atogepant)
    +
    ginseng, Asian
    1 interaction

    Monitor/Modify Tx

    atogepant + ginseng, Asian

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • glecaprevir
  • Qulipta (atogepant)
    +
    glecaprevir
    1 interaction

    Monitor/Modify Tx

    atogepant + glecaprevir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • glycerol phenylbutyrate
  • Qulipta (atogepant)
    +
    glycerol phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    atogepant + glycerol phenylbutyrate

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • griseofulvin
  • Qulipta (atogepant)
    +
    griseofulvin
    1 interaction

    Monitor/Modify Tx

    atogepant + griseofulvin

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • guanfacine
  • Qulipta (atogepant)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    atogepant + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hoodia
  • Qulipta (atogepant)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    atogepant + hoodia

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydralazine
  • Qulipta (atogepant)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    atogepant + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Qulipta (atogepant)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    atogepant + hydrochlorothiazide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrocortisone
  • Qulipta (atogepant)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    atogepant + hydrocortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydroxocobalamin IV
  • Qulipta (atogepant)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    atogepant + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibrutinib
  • Qulipta (atogepant)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    atogepant + ibrutinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibuprofen
  • Qulipta (atogepant)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    atogepant + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • idelalisib
  • Qulipta (atogepant)
    +
    idelalisib
    1 interaction

    Monitor/Modify Tx

    atogepant + idelalisib

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • indapamide
  • Qulipta (atogepant)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    atogepant + indapamide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • indomethacin
  • Qulipta (atogepant)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    atogepant + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • irbesartan
  • Qulipta (atogepant)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    atogepant + irbesartan

    monitor BP; CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects; may decr. antihypertensive agent efficacy (hepatic transport inhibited; antagonistic effects)

  • isradipine
  • Qulipta (atogepant)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    atogepant + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • itraconazole
  • Qulipta (atogepant)
    +
    itraconazole
    1 interaction

    Monitor/Modify Tx

    atogepant + itraconazole

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • ketamine
  • Qulipta (atogepant)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    atogepant + ketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketoconazole
  • Qulipta (atogepant)
    +
    ketoconazole
    1 interaction

    Monitor/Modify Tx

    atogepant + ketoconazole

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • ketoprofen
  • Qulipta (atogepant)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    atogepant + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketorolac
  • Qulipta (atogepant)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    atogepant + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • labetalol
  • Qulipta (atogepant)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    atogepant + labetalol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lanreotide
  • Qulipta (atogepant)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    atogepant + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leflunomide
  • Qulipta (atogepant)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    atogepant + leflunomide

    monitor BP; CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of HTN, other adverse effects (hepatic transport inhibited, additive effects)

  • leniolisib
  • Qulipta (atogepant)
    +
    leniolisib
    1 interaction

    Monitor/Modify Tx

    atogepant + leniolisib

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • lenvatinib
  • Qulipta (atogepant)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    atogepant + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • letermovir
  • Qulipta (atogepant)
    +
    letermovir
    1 interaction

    Monitor/Modify Tx

    atogepant + letermovir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • levalbuterol inhaled
  • Qulipta (atogepant)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + levalbuterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • levoketoconazole
  • Qulipta (atogepant)
    +
    levoketoconazole
    1 interaction

    Monitor/Modify Tx

    atogepant + levoketoconazole

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • levomilnacipran
  • Qulipta (atogepant)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    atogepant + levomilnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • licorice
  • Qulipta (atogepant)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    atogepant + licorice

    monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects)

  • lisdexamfetamine
  • Qulipta (atogepant)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    atogepant + lisdexamfetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lisinopril
  • Qulipta (atogepant)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    atogepant + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lonafarnib
  • Qulipta (atogepant)
    +
    lonafarnib
    1 interaction

    Monitor/Modify Tx

    atogepant + lonafarnib

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • losartan
  • Qulipta (atogepant)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    atogepant + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • luspatercept
  • Qulipta (atogepant)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    atogepant + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • magnesium salicylate
  • Qulipta (atogepant)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    atogepant + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • meclofenamate
  • Qulipta (atogepant)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    atogepant + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mefenamic acid
  • Qulipta (atogepant)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    atogepant + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

  • meloxicam
  • Qulipta (atogepant)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    atogepant + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methamphetamine
  • Qulipta (atogepant)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    atogepant + methamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Qulipta (atogepant)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    atogepant + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methyldopa
  • Qulipta (atogepant)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    atogepant + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Qulipta (atogepant)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    atogepant + methylergonovine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • methylphenidate
  • Qulipta (atogepant)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    atogepant + methylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methylprednisolone
  • Qulipta (atogepant)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    atogepant + methylprednisolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methyltestosterone
  • Qulipta (atogepant)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    atogepant + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metoclopramide
  • Qulipta (atogepant)
    +
    metoclopramide
    1 interaction

    Monitor/Modify Tx

    atogepant + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metolazone
  • Qulipta (atogepant)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    atogepant + metolazone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • metoprolol
  • Qulipta (atogepant)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    atogepant + metoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • midostaurin
  • Qulipta (atogepant)
    +
    midostaurin
    1 interaction

    Monitor/Modify Tx

    atogepant + midostaurin

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • mifepristone
  • Qulipta (atogepant)
    +
    mifepristone
    1 interaction

    Monitor/Modify Tx

    atogepant + mifepristone

    decr. atogepant dose to 10 mg/day during and x14 days after daily mifepristone use: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • milnacipran
  • Qulipta (atogepant)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    atogepant + milnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • minoxidil
  • Qulipta (atogepant)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    atogepant + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Qulipta (atogepant)
    +
    mirabegron
    1 interaction

    Monitor/Modify Tx

    atogepant + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mobocertinib
  • Qulipta (atogepant)
    +
    mobocertinib
    1 interaction

    Monitor/Modify Tx

    atogepant + mobocertinib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • moexipril
  • Qulipta (atogepant)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    atogepant + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nabumetone
  • Qulipta (atogepant)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    atogepant + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nadolol
  • Qulipta (atogepant)
    +
    nadolol
    1 interaction

    Monitor/Modify Tx

    atogepant + nadolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • naproxen
  • Qulipta (atogepant)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    atogepant + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naratriptan
  • Qulipta (atogepant)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naxitamab
  • Qulipta (atogepant)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    atogepant + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nebivolol
  • Qulipta (atogepant)
    +
    nebivolol
    1 interaction

    Monitor/Modify Tx

    atogepant + nebivolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nefazodone
  • Qulipta (atogepant)
    +
    nefazodone
    1 interaction

    Monitor/Modify Tx

    atogepant + nefazodone

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • nelfinavir
  • Qulipta (atogepant)
    +
    nelfinavir
    1 interaction

    Monitor/Modify Tx

    atogepant + nelfinavir

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • nevirapine
  • Qulipta (atogepant)
    +
    nevirapine
    1 interaction

    Monitor/Modify Tx

    atogepant + nevirapine

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • nicardipine
  • Qulipta (atogepant)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    atogepant + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nifedipine
  • Qulipta (atogepant)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    atogepant + nifedipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nimodipine
  • Qulipta (atogepant)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    atogepant + nimodipine

    monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

  • niraparib
  • Qulipta (atogepant)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    atogepant + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Qulipta (atogepant)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    atogepant + nisoldipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • norepinephrine
  • Qulipta (atogepant)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    atogepant + norepinephrine

    monitor BP: combo may incr. risk of severe HTN (additive effects)

  • obinutuzumab
  • Qulipta (atogepant)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    atogepant + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • odevixibat
  • Qulipta (atogepant)
    +
    odevixibat
    1 interaction

    Monitor/Modify Tx

    atogepant + odevixibat

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • olmesartan medoxomil
  • Qulipta (atogepant)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    atogepant + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • olodaterol inhaled
  • Qulipta (atogepant)
    +
    olodaterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + olodaterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • olutasidenib
  • Qulipta (atogepant)
    +
    olutasidenib
    1 interaction

    Monitor/Modify Tx

    atogepant + olutasidenib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism possibly induced)

  • omaveloxolone
  • Qulipta (atogepant)
    +
    omaveloxolone
    1 interaction

    Monitor/Modify Tx

    atogepant + omaveloxolone

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • osilodrostat
  • Qulipta (atogepant)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    atogepant + osilodrostat

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxaprozin
  • Qulipta (atogepant)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    atogepant + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxcarbazepine
  • Qulipta (atogepant)
    +
    oxcarbazepine
    1 interaction

    Monitor/Modify Tx

    atogepant + oxcarbazepine

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • oxymetazoline nasal
  • Qulipta (atogepant)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    atogepant + oxymetazoline nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxytocin
  • Qulipta (atogepant)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    atogepant + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Qulipta (atogepant)
    +
    ozanimod
    1 interaction

    Monitor/Modify Tx

    atogepant + ozanimod

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • pazopanib
  • Qulipta (atogepant)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    atogepant + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • perampanel
  • Qulipta (atogepant)
    +
    perampanel
    1 interaction

    Monitor/Modify Tx

    atogepant + perampanel

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy if on perampanel 12 mg/day (hepatic metabolism induced)

  • perindopril
  • Qulipta (atogepant)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    atogepant + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phendimetrazine
  • Qulipta (atogepant)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    atogepant + phendimetrazine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenoxybenzamine
  • Qulipta (atogepant)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    atogepant + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Qulipta (atogepant)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    atogepant + phentermine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phentolamine
  • Qulipta (atogepant)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    atogepant + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Qulipta (atogepant)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    atogepant + phenylephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine injection
  • Qulipta (atogepant)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    atogepant + phenylephrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine nasal
  • Qulipta (atogepant)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    atogepant + phenylephrine nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine ophthalmic
  • Qulipta (atogepant)
    +
    phenylephrine ophthalmic
    1 interaction

    Monitor/Modify Tx

    atogepant + phenylephrine ophthalmic

    monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN (additive effects)

  • phenylephrine rectal
  • Qulipta (atogepant)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    atogepant + phenylephrine rectal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pibrentasvir
  • Qulipta (atogepant)
    +
    pibrentasvir
    1 interaction

    Monitor/Modify Tx

    atogepant + pibrentasvir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • pindolol
  • Qulipta (atogepant)
    +
    pindolol
    1 interaction

    Monitor/Modify Tx

    atogepant + pindolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pioglitazone
  • Qulipta (atogepant)
    +
    pioglitazone
    1 interaction

    Monitor/Modify Tx

    atogepant + pioglitazone

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • piroxicam
  • Qulipta (atogepant)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    atogepant + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ponatinib
  • Qulipta (atogepant)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    atogepant + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ponesimod
  • Qulipta (atogepant)
    +
    ponesimod
    1 interaction

    Monitor/Modify Tx

    atogepant + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • posaconazole
  • Qulipta (atogepant)
    +
    posaconazole
    1 interaction

    Monitor/Modify Tx

    atogepant + posaconazole

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • pralsetinib
  • Qulipta (atogepant)
    +
    pralsetinib
    1 interaction

    Monitor/Modify Tx

    atogepant + pralsetinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • prazosin
  • Qulipta (atogepant)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    atogepant + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Qulipta (atogepant)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    atogepant + prednisolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • prednisone
  • Qulipta (atogepant)
    +
    prednisone
    1 interaction

    Monitor/Modify Tx

    atogepant + prednisone

    monitor BP; CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

  • propranolol
  • Qulipta (atogepant)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    atogepant + propranolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pseudoephedrine
  • Qulipta (atogepant)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    atogepant + pseudoephedrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • quetiapine
  • Qulipta (atogepant)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    atogepant + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

  • quinapril
  • Qulipta (atogepant)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    atogepant + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramipril
  • Qulipta (atogepant)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    atogepant + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Qulipta (atogepant)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    atogepant + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • regorafenib
  • Qulipta (atogepant)
    +
    regorafenib
    1 interaction

    Monitor/Modify Tx

    atogepant + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • resmetirom
  • Qulipta (atogepant)
    +
    resmetirom
    1 interaction

    Monitor/Modify Tx

    atogepant + resmetirom

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • ribociclib
  • Qulipta (atogepant)
    +
    ribociclib
    1 interaction

    Monitor/Modify Tx

    atogepant + ribociclib

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • rilzabrutinib
  • Qulipta (atogepant)
    +
    rilzabrutinib
    1 interaction

    Monitor/Modify Tx

    atogepant + rilzabrutinib

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport possibly inhibited)

  • ripretinib
  • Qulipta (atogepant)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    atogepant + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ritonavir
  • Qulipta (atogepant)
    +
    ritonavir
    1 interaction

    Monitor/Modify Tx

    atogepant + ritonavir

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • rizatriptan
  • Qulipta (atogepant)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ropinirole
  • Qulipta (atogepant)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    atogepant + ropinirole

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rotigotine transdermal
  • Qulipta (atogepant)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    atogepant + rotigotine transdermal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rufinamide
  • Qulipta (atogepant)
    +
    rufinamide
    1 interaction

    Monitor/Modify Tx

    atogepant + rufinamide

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • sacubitril
  • Qulipta (atogepant)
    +
    sacubitril
    1 interaction

    Monitor/Modify Tx

    atogepant + sacubitril

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • salmeterol inhaled
  • Qulipta (atogepant)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + salmeterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • salsalate
  • Qulipta (atogepant)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    atogepant + salsalate

    monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

  • sarilumab
  • Qulipta (atogepant)
    +
    sarilumab
    1 interaction

    Monitor/Modify Tx

    atogepant + sarilumab

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

  • selpercatinib
  • Qulipta (atogepant)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    atogepant + selpercatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • siponimod
  • Qulipta (atogepant)
    +
    siponimod
    1 interaction

    Monitor/Modify Tx

    atogepant + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • solriamfetol
  • Qulipta (atogepant)
    +
    solriamfetol
    1 interaction

    Monitor/Modify Tx

    atogepant + solriamfetol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sorafenib
  • Qulipta (atogepant)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    atogepant + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • spironolactone
  • Qulipta (atogepant)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    atogepant + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • stiripentol
  • Qulipta (atogepant)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    atogepant + stiripentol

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism possibly induced)

  • sulindac
  • Qulipta (atogepant)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    atogepant + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sumatriptan
  • Qulipta (atogepant)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Qulipta (atogepant)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    atogepant + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunvozertinib
  • Qulipta (atogepant)
    +
    sunvozertinib
    1 interaction

    Monitor/Modify Tx

    atogepant + sunvozertinib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • suzetrigine
  • Qulipta (atogepant)
    +
    suzetrigine
    1 interaction

    Monitor/Modify Tx

    atogepant + suzetrigine

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • tacrolimus
  • Qulipta (atogepant)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    atogepant + tacrolimus

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tagraxofusp
  • Qulipta (atogepant)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    atogepant + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tazemetostat
  • Qulipta (atogepant)
    +
    tazemetostat
    1 interaction

    Monitor/Modify Tx

    atogepant + tazemetostat

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • tecovirimat
  • Qulipta (atogepant)
    +
    tecovirimat
    1 interaction

    Monitor/Modify Tx

    atogepant + tecovirimat

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • telmisartan
  • Qulipta (atogepant)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    atogepant + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terazosin
  • Qulipta (atogepant)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    atogepant + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Qulipta (atogepant)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    atogepant + terbutaline

    monitor BP: combo may incr. risk of HTN (additive effects)

  • teriflunomide
  • Qulipta (atogepant)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    atogepant + teriflunomide

    monitor BP; CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of HTN, other adverse effects (hepatic transport inhibited, additive effects)

  • testosterone
  • Qulipta (atogepant)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    atogepant + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • timolol
  • Qulipta (atogepant)
    +
    timolol
    1 interaction

    Monitor/Modify Tx

    atogepant + timolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tipranavir
  • Qulipta (atogepant)
    +
    tipranavir
    1 interaction

    Monitor/Modify Tx

    atogepant + tipranavir

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited, hepatic transport inhibited)

  • tivozanib
  • Qulipta (atogepant)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    atogepant + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • tocilizumab
  • Qulipta (atogepant)
    +
    tocilizumab
    1 interaction

    Monitor/Modify Tx

    atogepant + tocilizumab

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

  • tolmetin
  • Qulipta (atogepant)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    atogepant + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • topiramate
  • Qulipta (atogepant)
    +
    topiramate
    1 interaction

    Monitor/Modify Tx

    atogepant + topiramate

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy, especially with topiramate doses >200 mg/day (hepatic metabolism induced)

  • torsemide
  • Qulipta (atogepant)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    atogepant + torsemide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tovorafenib
  • Qulipta (atogepant)
    +
    tovorafenib
    1 interaction

    Monitor/Modify Tx

    atogepant + tovorafenib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • trametinib
  • Qulipta (atogepant)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    atogepant + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • trandolapril
  • Qulipta (atogepant)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    atogepant + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triamcinolone
  • Qulipta (atogepant)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    atogepant + triamcinolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • triamterene
  • Qulipta (atogepant)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    atogepant + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tucatinib
  • Qulipta (atogepant)
    +
    tucatinib
    1 interaction

    Monitor/Modify Tx

    atogepant + tucatinib

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • vadadustat
  • Qulipta (atogepant)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    atogepant + vadadustat

    monitor BP; CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of HTN (including hypertensive crisis), other adverse effects (hepatic transport inhibited, additive effects)

  • valsartan
  • Qulipta (atogepant)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    atogepant + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vamorolone
  • Qulipta (atogepant)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    atogepant + vamorolone

    monitor BP; CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy; may incr. risk of HTN (hepatic metabolism possibly induced; additive effects)

  • vandetanib
  • Qulipta (atogepant)
    +
    vandetanib
    1 interaction

    Monitor/Modify Tx

    atogepant + vandetanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vasopressin
  • Qulipta (atogepant)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    atogepant + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • velpatasvir
  • Qulipta (atogepant)
    +
    velpatasvir
    1 interaction

    Monitor/Modify Tx

    atogepant + velpatasvir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • vemurafenib
  • Qulipta (atogepant)
    +
    vemurafenib
    1 interaction

    Monitor/Modify Tx

    atogepant + vemurafenib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • venlafaxine
  • Qulipta (atogepant)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    atogepant + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • verapamil
  • Qulipta (atogepant)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    atogepant + verapamil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vilanterol inhaled
  • Qulipta (atogepant)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    atogepant + vilanterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • viloxazine
  • Qulipta (atogepant)
    +
    viloxazine
    1 interaction

    Monitor/Modify Tx

    atogepant + viloxazine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vinblastine
  • Qulipta (atogepant)
    +
    vinblastine
    1 interaction

    Monitor/Modify Tx

    atogepant + vinblastine

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • voclosporin
  • Qulipta (atogepant)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    atogepant + voclosporin

    monitor BP; CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of HTN, other adverse effects (hepatic transport inhibited, additive effects)

  • vorasidenib
  • Qulipta (atogepant)
    +
    vorasidenib
    1 interaction

    Monitor/Modify Tx

    atogepant + vorasidenib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism possibly induced)

  • voriconazole
  • Qulipta (atogepant)
    +
    voriconazole
    1 interaction

    Monitor/Modify Tx

    atogepant + voriconazole

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • voxilaprevir
  • Qulipta (atogepant)
    +
    voxilaprevir
    1 interaction

    Monitor/Modify Tx

    atogepant + voxilaprevir

    CHRONIC MIGRAINE: decr. atogepant dose to 30 mg/day; EPISODIC MIGRAINE: decr. atogepant dose to 10 or 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

  • yohimbe
  • Qulipta (atogepant)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    atogepant + yohimbe

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zanubrutinib
  • Qulipta (atogepant)
    +
    zanubrutinib
    1 interaction

    Monitor/Modify Tx

    atogepant + zanubrutinib

    CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

  • ziv-aflibercept
  • Qulipta (atogepant)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    atogepant + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zolmitriptan
  • Qulipta (atogepant)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    atogepant + zolmitriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

  • elexacaftor/tezacaftor/ivacaftor
  • Qulipta (atogepant)
    +
    elexacaftor/ tezacaftor/ ivacaftor
    1 interaction

    Caution Advised

    atogepant + elexacaftor/ tezacaftor/ ivacaftor

    caution advised: combo may incr. atogepant levels, risk of adverse effects (hepatic transport possibly inhibited)

  • meropenem
  • Qulipta (atogepant)
    +
    meropenem
    1 interaction

    Caution Advised

    atogepant + meropenem

    caution advised: combo may decr. atogepant levels, efficacy (hepatic metabolism possibly induced)

  • pretomanid
  • Qulipta (atogepant)
    +
    pretomanid
    1 interaction

    Caution Advised

    atogepant + pretomanid

    caution advised: combo may incr. atogepant levels, risk of adverse effects (hepatic transport possibly inhibited)

  • vaborbactam
  • Qulipta (atogepant)
    +
    vaborbactam
    1 interaction

    Caution Advised

    atogepant + vaborbactam

    caution advised: combo may decr. atogepant levels, efficacy (hepatic metabolism possibly induced)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@14e5518d
  • hypersensitivity reaction
  • anaphylaxis
  • angioedema
  • HTN
  • Raynaud phenomenon

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@2f235fa8
  • nausea
  • constipation
  • weight decr.
  • fatigue
  • somnolence
  • appetite decr.
  • dizziness
  • ALT or AST elevated

Safety/Monitoring .

Monitoring Parameters
Cr at baseline; BP

Pregnancy/Lactation .

Pregnancy

Clinical Summary

weigh risk/benefit during pregnancy; no human data available; possible risk of decr. fetal wt and skeletal ossification based on animal data at >4x MRHD and risk of fetal visceral or skeletal abnormalities based on animal data at >3x MRHD

Pregnancy Registry

encourage patients to enroll in Empress Pregnancy Registry at 1-833-277-0206 or www.empresspregnancyregistry.com

Lactation

Clinical Summary

weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm, though drug excreted into milk; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@2d43cb28

Metabolism: for atogepant: unknown; CYP450: 3A4 substrate

Excretion: for atogepant: feces 42% (100% unchanged), urine 5% (100% unchanged); Half-life: 11h

Subclass: CGRP Inhibitors ; Headache/Migraine

Mechanism of Action
for atogepant: blocks calcitonin gene-related peptide (CGRP) activity

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: AbbVie Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@1154a66d

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information